Zogenix (NASDAQ:ZGNX) Stock Rating Lowered by BidaskClub

Zogenix (NASDAQ:ZGNX) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, April 10th.

ZGNX has been the topic of a number of other research reports. Leerink Swann upped their target price on shares of Zogenix from $50.00 to $54.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd. Mizuho restated a “buy” rating and issued a $51.00 price target on shares of Zogenix in a research report on Thursday, February 1st. Zacks Investment Research upgraded shares of Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Thursday, March 15th. Finally, ValuEngine upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $53.20.

How to Become a New Pot Stock Millionaire

NASDAQ ZGNX traded up $1.30 on Tuesday, reaching $41.55. The company’s stock had a trading volume of 596,919 shares, compared to its average volume of 561,168. The stock has a market cap of $1,375.24, a P/E ratio of -10.14 and a beta of 1.68. Zogenix has a 52 week low of $10.05 and a 52 week high of $45.85.

Zogenix (NASDAQ:ZGNX) last posted its earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.17). During the same quarter last year, the company earned ($0.95) EPS. equities analysts predict that Zogenix will post -3.12 EPS for the current year.

In other Zogenix news, Director Roger Hawley sold 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total value of $1,564,850.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.60% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in Zogenix during the third quarter worth $226,000. Sterling Capital Management LLC acquired a new position in Zogenix during the third quarter worth $237,000. Teacher Retirement System of Texas acquired a new position in Zogenix during the fourth quarter worth $409,000. Raymond James & Associates acquired a new position in Zogenix during the fourth quarter worth $460,000. Finally, Guggenheim Capital LLC boosted its holdings in Zogenix by 71.2% during the fourth quarter. Guggenheim Capital LLC now owns 12,843 shares of the company’s stock worth $514,000 after purchasing an additional 5,342 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Zogenix (NASDAQ:ZGNX) Stock Rating Lowered by BidaskClub” was first reported by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://macondaily.com/2018/04/17/zogenix-zgnx-downgraded-to-hold-at-bidaskclub-updated.html.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply